Veterans Seek Ibogaine Treatment Abroad Amid US Restrictions

Ibogaine remains illegal under US federal law, but some veterans are traveling abroad to access treatment for trauma-related conditions. Recent research and nonprofit initiatives have focused on supporting these veterans as interest in psychedelic-assisted therapy grows.

Ibogaine is classified as a Schedule I controlled substance in the United States, making it unlawful to possess, distribute, or use within the country. Despite this, clinics in countries such as Mexico, the Bahamas, Canada, the Netherlands, South Africa, and New Zealand operate in legal gray areas where ibogaine is not explicitly prohibited.

Veterans Exploring Treatment Solutions (VETS, Inc.) and Heroic Hearts Project are among the organizations that have supported US veterans seeking ibogaine and other psychedelic therapies abroad. VETS, Inc. has provided grants to over 1,000 veterans and their spouses since 2019, while Heroic Hearts Project connects veterans with treatment providers and offers support before and after therapy.

In Mexico, veterans often receive ibogaine in clinics with medical supervision, including ACLS-certified staff, cardiac monitoring, and pre-screening protocols. These clinics are frequently vetted by organizations such as VETS and Heroic Hearts Project to ensure safety standards are met.

What the numbers show

• Texas allocated $50 million in 2025 for ibogaine clinical trials
• Over 1,000 veterans and spouses received grants for psychedelic therapy since 2019
• Stanford-linked study reported 88% reduction in PTSD symptoms one month after ibogaine treatment
• Veterans’ average disability rating improved from 30.2 to 5.1 after treatment

A Stanford University-linked study involving 30 special operations veterans treated with ibogaine in Mexico found substantial reductions in symptoms of PTSD, depression, and anxiety. These improvements were sustained at least one month after treatment, according to published findings.

In the same study, veterans with traumatic brain injury and psychiatric symptoms experienced average reductions of 88% in PTSD symptoms, 87% in depression, and 81% in anxiety one month after receiving ibogaine. The average disability rating on the World Health Organization’s assessment scale improved from about 30.2 to 5.1 following treatment.

Ibogaine treatment is associated with serious cardiac risks, including potentially fatal heart rhythm abnormalities. However, some medically supervised studies have reported no serious cardiac events when proper protocols are followed.

Texas allocated $50 million in 2025 to support clinical trials of ibogaine through a public-private partnership involving a university, hospital, and drug developer. This investment represents the largest public funding for psychedelic research in the United States to date.

* This article is based on publicly available information at the time of writing.